Oppenheimer Cuts Boston Scientific (NYSE:BSX) Price Target to $100.00

Boston Scientific (NYSE:BSX) had its price target lowered by Oppenheimer from $125.00 to $100.00 in a research report report published on Friday, MarketBeat Ratings reports. Oppenheimer currently has an outperform rating on the medical equipment provider’s stock.

BSX has been the subject of a number of other research reports. Weiss Ratings reissued a “buy (b-)” rating on shares of Boston Scientific in a report on Wednesday, October 8th. Needham & Company LLC reiterated a “buy” rating on shares of Boston Scientific in a research note on Thursday. Leerink Partners increased their price target on Boston Scientific from $127.00 to $128.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 1st. Cowen reaffirmed a “buy” rating on shares of Boston Scientific in a report on Thursday, December 11th. Finally, Truist Financial reduced their target price on Boston Scientific from $130.00 to $120.00 and set a “buy” rating on the stock in a report on Thursday, December 18th. Two analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and two have issued a Hold rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Buy” and an average target price of $123.89.

Boston Scientific Stock Performance

BSX opened at $88.13 on Friday. The company has a debt-to-equity ratio of 0.47, a current ratio of 1.51 and a quick ratio of 0.96. The business has a fifty day simple moving average of $96.90 and a 200 day simple moving average of $100.27. Boston Scientific has a 1 year low of $85.98 and a 1 year high of $109.50. The company has a market capitalization of $130.65 billion, a PE ratio of 47.13, a price-to-earnings-growth ratio of 1.56 and a beta of 0.67.

Boston Scientific (NYSE:BSX) last posted its earnings results on Wednesday, October 22nd. The medical equipment provider reported $0.75 earnings per share for the quarter, topping analysts’ consensus estimates of $0.71 by $0.04. Boston Scientific had a return on equity of 19.46% and a net margin of 14.43%.The company had revenue of $5.07 billion during the quarter, compared to the consensus estimate of $4.97 billion. During the same quarter last year, the firm earned $0.63 earnings per share. The company’s revenue was up 20.3% on a year-over-year basis. Boston Scientific has set its FY 2025 guidance at 3.020-3.040 EPS and its Q4 2025 guidance at 0.770-0.790 EPS. Research analysts expect that Boston Scientific will post 2.85 EPS for the current year.

Insider Transactions at Boston Scientific

In related news, EVP Arthur C. Butcher sold 17,313 shares of the company’s stock in a transaction on Monday, December 1st. The stock was sold at an average price of $101.55, for a total transaction of $1,758,135.15. Following the completion of the sale, the executive vice president directly owned 23,600 shares in the company, valued at $2,396,580. This represents a 42.32% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, EVP Joseph Michael Fitzgerald sold 50,000 shares of the firm’s stock in a transaction dated Monday, November 3rd. The shares were sold at an average price of $99.47, for a total value of $4,973,500.00. Following the completion of the sale, the executive vice president directly owned 178,342 shares in the company, valued at $17,739,678.74. This trade represents a 21.90% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders sold 93,095 shares of company stock valued at $9,305,450. Corporate insiders own 0.50% of the company’s stock.

Hedge Funds Weigh In On Boston Scientific

Institutional investors have recently added to or reduced their stakes in the stock. GAMMA Investing LLC lifted its position in shares of Boston Scientific by 15.4% during the 2nd quarter. GAMMA Investing LLC now owns 29,486 shares of the medical equipment provider’s stock valued at $3,167,000 after buying an additional 3,932 shares during the last quarter. State Street Corp raised its stake in Boston Scientific by 1.1% in the 2nd quarter. State Street Corp now owns 65,191,864 shares of the medical equipment provider’s stock valued at $7,002,258,000 after acquiring an additional 713,379 shares during the period. Synergy Asset Management LLC raised its stake in Boston Scientific by 3,493.0% in the 3rd quarter. Synergy Asset Management LLC now owns 493,323 shares of the medical equipment provider’s stock valued at $48,297,000 after acquiring an additional 479,593 shares during the period. Gladstone Institutional Advisory LLC lifted its holdings in Boston Scientific by 39.5% during the third quarter. Gladstone Institutional Advisory LLC now owns 51,884 shares of the medical equipment provider’s stock valued at $5,065,000 after purchasing an additional 14,700 shares during the last quarter. Finally, Bank Pictet & Cie Europe AG boosted its position in Boston Scientific by 75.3% during the second quarter. Bank Pictet & Cie Europe AG now owns 164,654 shares of the medical equipment provider’s stock worth $17,685,000 after purchasing an additional 70,753 shares during the period. 89.07% of the stock is currently owned by institutional investors and hedge funds.

Key Boston Scientific News

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Acquisition expands addressable market — The agreement to buy Penumbra (~$14.5B enterprise value) gives Boston Scientific scaled entry into mechanical thrombectomy and neurovascular devices, which management says accelerates growth in fast-growing vascular segments. Read More.
• Positive Sentiment: Wall Street support remains — TD Cowen reiterated a Buy and other analysts emphasize the deal as a strategic growth catalyst and valuation support ahead of 2026 expectations. Read More.
• Neutral Sentiment: Price-target and analyst notes are mixed — Oppenheimer trimmed its target from $125 to $100 but kept an Outperform rating, indicating continued upside though with more cautious near-term expectations. Read More.
• Neutral Sentiment: Technical/turnaround commentary — Some market commentators note BSX is technically oversold and that consensus earnings revisions are turning positive, which could support a rebound over time. Read More.
• Neutral Sentiment: Smaller tuck-ins continue — Boston Scientific’s other recent deals (e.g., Valencia Technologies) broaden product offerings in urology and ITNS, a modest near-term boost versus the Penumbra scale. Read More.
• Negative Sentiment: Shares sold off on the deal announcement — The market reacted negatively to the size/structure of the transaction and near-term uncertainty, and BSX shares traded down after the news. Read More.
• Negative Sentiment: Legal/approval uncertainty — Law firms have launched investor inquiries into the adequacy of Penumbra’s sale process and price; this increases deal execution risk and could prolong integration or regulatory review. Read More.
• Negative Sentiment: Derivative-market hedging and bearish interest spiked — Unusually large put option volume indicates some investors are hedging or betting on further downside, adding volatility risk. Read More.
• Negative Sentiment: Mixed analyst commentary and skeptic pieces — Several independent commentaries and Seeking Alpha pieces highlight concerns about price paid and strategic fit, underscoring near-term skepticism despite long-term promise. Read More.

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.